Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955926 | 0.84 | AR (0.57) | ARKCNH2DPP4HSD17B10PIM1 | |
| SCHEMBL9956970 | 0.83 | DPP4 (0.58) | ARKCNH2DPP4HSD17B10KDM4E | |
| SCHEMBL9956561 | 0.82 | DPP4 (0.63) | ARKCNH2DPP4HSD17B10PIM1 | |
| SCHEMBL3356219 | 0.76 | CSNK1E (0.50) | ARKCNH2DPP4CSNK1EDRD2 | |
| SCHEMBL2262726 | 0.75 | AR (1.00) | ARKCNH2DPP4HSD17B10PIM1 | |
| SCHEMBL2263330 | 0.72 | AR (0.92) | ARKCNH2DPP4HSD17B10PIM1 | |
| SCHEMBL1394316 | 0.71 | MAPK14 (0.49) | ARKCNH2DPP4CSNK1EDRD2 | |
| SCHEMBL3106544 | 0.71 | CSNK1E (0.66) | CSNK1E | |
| SCHEMBL9956616 | 0.70 | DPP4 (0.49) | ARKCNH2DPP4KDM4ESMN1; SMN2 | |
| SCHEMBL2269097 | 0.70 | AR (0.88) | ARKCNH2DPP4HSD17B10PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | claimed |
| EP-2635578-B1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI USA LTD (US) | 2015-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PRXL2A, CDK2, CCNA2 | AR 335/4885KCNH2 584/4885DPP4 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.